Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Aims For Flexibility In Upcoming Drug/Test Co-Development Guidance

This article was originally published in The Gray Sheet

Executive Summary

FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed

You may also be interested in...

FDA Plans Guidance This Year On Co-Development Of Diagnostics And Drugs

FDA expects to complete a guidance document on co-development of diagnostics and drugs used for personalized medicine by the end of this year, FDA Commissioner Margaret Hamburg said at a meeting in Washington, D.C., Feb. 25

MedCAC Supports Some PGx Test Regimens, But Calls For Overall Better Data

There is enough strong evidence to show that a select few pharmacogenomic (PGx) tests can be applied in a manner that positively affects patient outcomes, members of a CMS advisory panel concluded Jan. 27

Dx Groups To FDA: Time For Companion Diagnostics Guidance Is Now

Industry groups representing test manufacturers, labs, drug firms and others are redoubling their pressure on FDA to clarify the regulatory requirements for co-development of diagnostics and drug treatments

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts